Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588036 | 0.85 | CYP2A6 (0.54) | CYP1A2PARP1ACHEPARP10CYP2A6 | |
| SCHEMBL3267926 | 0.85 | CYP2A6 (0.54) | CYP1A2PARP1ACHEPARP10CYP2A6 | |
| Ammonia Solution, Strong SCHEMBL2208350 | 0.82 | — | — | |
| Water SCHEMBL28759228 | 0.82 | — | — | |
| SCHEMBL12430513 | 0.81 | NPC1 (0.42) | CYP1A2PARP1ACHEPARP10CYP2A6 | |
| SCHEMBL6936889 | 0.81 | NPC1 (0.42) | PARP1ACHEPARP10CYP2A6NOTUM | |
| SCHEMBL9288568 | 0.78 | PARP10 (0.51) | CYP1A2PARP10TDP2CYP2C19 | |
| SCHEMBL6907006 | 0.78 | CA1 (0.44) | CYP1A2PARP1ACHECYP2A6CA1 | |
| SCHEMBL9432863 | 0.74 | CYP1A2 (0.46) | CYP1A2CYP2A6 | |
| SCHEMBL11140087 | 0.73 | MAOA (0.57) | CYP1A2PARP1ACHEPARP10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-117751126-A | Oxaspiro derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-116096712-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023011422-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-5968954-A | EXHIBIT SELECTIVE BINDING AFFINITY FOR 5-HYDROXYTRYPTAMINE RECEPTORS | ADIR ET COMPAGNIE (FR) | 1999-10-19 | — | — | US | disclosed |
| CN-1218051-A | New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-06-02 | — | — | CN | disclosed |
| EP-0861837-A1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-09-02 | — | — | EP | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4217302-A | INSECTICIDES, MITICIDES | ZOECON CORPORATION (US) | 1980-08-12 | — | — | US | disclosed |
| US-4189598-A | INSECTICIDES., MITICIDE | ZOECON CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | CYP1A2 1611/4885PARP1 373/4885ACHE 278/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | CYP1A2 1611/4885PARP1 373/4885ACHE 278/4885 |
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | CYP1A2 4798/4885PARP1 2192/4885ACHE 2497/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | CYP1A2 408/4885PARP1 2697/4885ACHE 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.